Overview
EDSA market data
Price History
EDSA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.93 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,935.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.72 – $20.32 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $51.9M · P/B 1.40 · P/S 157.92.
Company News
Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) EstimateBenzinga · Aug 13, 2026, 8:45 PM
8-K filing — Edesa Biotech, Inc. (EDSA)SEC EDGAR · Aug 13, 2026, 8:20 PM
Edesa Biotech shares are trading higher after the company announced a $3.5 million private placement of common shares.Benzinga · Jun 11, 2026, 5:06 PM
Edesa Biotech Announces Exploratory Data For Its Anti-TLR4 Monoclonal Antibody Paridiprubart In Patients With Acute Kidney Injury And Respiratory Distress; Analyses Demonstrate Mortality ReductionBenzinga · Jun 5, 2026, 1:30 PM
Acute Respiratory Distress Syndrome Market to Grow Steadily at a 3.8% CAGR Through 2036, Supported by Emerging ARDS Therapies | DelveInsightGlobenewswire Inc · Jun 3, 2026, 5:15 PM
Edesa Biotech Q2 EPS $(0.49) Misses $(0.26) EstimateBenzinga · May 14, 2026, 8:50 PM